Limiting allogeneic bone marrow transplantation based on psychosocial criteria: A comparison of professional attitudes  by McLellan, L. et al.
SCID model, comparing transplantation of 1  106 CD34 cells,
cotransplantation of 5  105 untransduced mesenchymal cells and
1  106 CD34 cells and cotransplantation of 5  105 IL-7
engineered stromal cells with 1  106 CD34 cells, the last
improved engraftment in terms of CD45 cells and signiﬁcantly
increased the CD3 cell count in peripheral blood (1.4 	 1.6 vs
7.4 	 3; P  .05), bone marrow (0.8 	 1 vs 5.5 	 2; P  .05) and
spleen (0.08 	 0.1 vs 6.2 	 2; P  .05). No signiﬁcant differences
emerged in CD19 cell recovery. IL-7 serum concentrations did
not vary at any time point posttransplantation. These data dem-
onstrate that IL-7-transduced stromal cells maintain the naive
T-cell phenotype (CD45RA/CD45RO) in vitro and serve to
improve immunologic reconstitution after HSCT in NOD/SCID
mice, thus emerging as an ideal scaffold for hastening immunolog-
ical recovery in T-cell-deﬁcient hosts.
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LIMITING ALLOGENEIC BONE MARROW TRANSPLANTATION BASED
ON PSYCHOSOCIAL CRITERIA: A COMPARISON OF PROFESSIONAL AT-
TITUDES
McLellan, L.1; Foster, L.2; Kuczkowski, E.1; Dabney, J.1; Welsh, E.1;
Bell, K.1; Rini, B.1; Bates, J.1; Curtis, J.1; Bolwell, B.J.1 1. The
Cleveland Clinic Foundation, Cleveland, OH; 2. Cleveland State Uni-
versity, Cleveland, OH.
Oncologists specializing in bone marrow transplantation (BMT)
make decisions about who is an appropriate medical candidate for
an allogeneic BMT based on clinical criteria. It is not clear how
and if decisions are made as to whether a patient is an appropriate
candidate based on psychosocial criteria. Although setting limits
based on such criteria has been researched in solid organ trans-
plantation, this is not the case in BMT. Presented will be results
from survey research comparing responses of BMT physicians,
social workers, and nurses regarding acceptability of select psycho-
social screening criteria in allogeneic BMT. An IRB-approved
survey was mailed to members of ASBMT (North America),
AOSW, BMT Special Interest Group, and ONS BMT Special
Interest Group. Respondents were asked whether they would rec-
ommend proceeding or not proceeding with allogeneic BMT in 17
case vignettes, all of in which the patient has leukemia and had a
matched donor. Based on 262 physician surveys returned (40%
response rate), the following are 7 case vignettes in which the
majority stated that they would recommend not proceeding: active
suicidal ideation (84%), current use of addictive illicit drugs (76%),
noncompliance (76%), no caregiver available posttransplantation
(69%), active alcoholism (61%), early onset of Alzheimer’s disease
(55%), and no means to pay for BMT (51%). In 10 of 17 case
vignettes, most physician respondents would recommend proceed-
ing: history of prior suicide attempts but not currently suicidal
(86%), mild mental retardation (84%), major depression (84%),
controlled schizophrenia (82%), daily marijuana use (82%), history
of a violent felony crime (81%), borderline personality disorder
(79%), tobacco smoking (79%), morbid obesity (71%), and care-
giver with mental health problem (65%). These initial ﬁndings
infer that whether or not physicians decide to proceed with allo-
geneic BMT may be contingent on the currency and acuity of
psychosocial risk factors predictive of impaired patient ability for
informed, competent decision-making. Responses of physicians,
nurses, and social workers are compared and implications for
clinical practice in BMT discussed.
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HSCT FAMILY CAREGIVER QUALITY OF LIFE INFLUENCED BY HIGH
CAREGIVING STRAIN AND LOW PREDICTABILITY OF CAREGIVING
Eldredge, D.H.1, Nail, L.M.1, Grant, M.2, Maziarz, R.T.1 1. Oregon
Health Science University, Portland, OR; 2. City of Hope Comprehensive
Cancer Center, Duarte, CA.
Background/Purpose: Family caregivers (FCGs) provide much
of the outpatient care for allogeneic HSCT recipients during the
ﬁrst year after transplantation. Despite the importance of family
caregiving, there is little information about the types of care ac-
tivities required during this period and the effect of caregiving role
strain (CRS) on FCGs’ quality of life (QOL). The purpose of this
study is to describe relationships among preparedness for caregiv-
ing, predictability of caregiving, recipient function and CRS on
FCG QOL. Methods: FCGs (N  56) were recruited from 2
academic medical centers on the West Coast and completed a
single questionnaire between 3 and 15 months (mean, 7.7 months)
after family members’ allogeneic HSCT. Descriptive statistics,
correlation, and simultaneous regression techniques were used in
this cross-sectional study. Results: Three types of caregiving were
inductively derived from 100 activities: (1) performing usual care
(eg, supervising scheduled medications, keeping house clean), (2)
providing emotional support (eg, talking with HSCT recipients
when sad, discussing how people respond to recipients’ illness), and
(3) making care-based decisions (eg, giving prn medications, no-
ticing subtle changes). Providing emotional support was the most
difﬁcult type of caregiving activity (mean, 1.81; range, 0  not
done, 1  easy, to 5  very hard). FCGs had little difﬁculty
performing usual care (mean, 0.90) and making care-based deci-
sions (mean, 1.28). FCGs felt moderately well prepared for care-
giving (mean, 2.9; range, 1–4). Together, preparedness, recipient
function, predictability, and the 3 types of caregiving accounted for
37% of the variance in FCG QOL (F6,48 7.3; P  .001). FCG
QOL was uniquely predicted by predictability of caregiving (t48 
2.5; P  .02) and strain from providing emotional support (t48 
1.9; P .05). Conclusions:During the ﬁrst year after allogeneic
HSCT, FCGs need ongoing assistance providing emotional sup-
port to HSCT recipients and recognizing predictability of recipi-
ents’ caregiving needs.
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EARLY ALLOGENEIC STEM CELL TRANSPLANTATION FOR YOUNG
ADULTS WITH ACUTE MYELOBLASTIC LEUKEMIA IN FIRST COMPLETE
REMISSION: AN INTENT-TO-TREAT ANALYSIS OF THE LONG-TERM
EXPERIENCE OF THE BGMT GROUP
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Bardou, V.J.4; Blaise, D.4 1. Centre Hospitalier de Caremeau, Nimes,
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eyronie, Montpellier, France.
We evaluated the outcome of early allo-SCT through 4 succes-
sive protocols over 17 years by an intent-to-treat analysis based on
donor availability in patients younger than 45 years with CR1
AML. Of the 472 patients achieving CR, 182 had an HLA-iden-
tical sibling identiﬁed, and allo-SCT was carried out in 171 (94%)
after Cy-TBI. Of the 290 patients without donor, 88% were
intended (and 63% received) to receive autologous auto-SCT.
With a median follow-up of 114 months, the 10-year probabilities
of relapse, nonrelapse death, overall survival (OS), and leukemia-
free survival (LFS) were 27% versus 55% (P  .001), 24% versus
6% (P  .001), 51% versus 43% (P  .11), and 48% versus 40%
(P  .03), respectively, for alloSCT and non-alloSCT treatment.
Cox analysis identiﬁed initial WBC, FAB subtypes, cytogenetic
risk group, and number of induction courses to achieve CR as
signiﬁcant prognostic predictors. We calculated the statistical risk
of each combination of these 4 factors for patients not having a
suitable donor and identiﬁed 3 groups of patients with different
outcome (poor, intermediate, and standard risk group). This anal-
ysis allowed us to reclassify 21% of the patients as compared with
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